Under the collaboration, VAGLAHS will gain access to Progenics’ AI imaging analysis platforms, specifically the automated Bone Scan Index (aBSI) and
Progenics Pharmaceuticals has entered a collaboration with Veteran Affairs Greater Los Angeles Healthcare System (VAGLAHS) to support the development of new machine learning tools aimed at improving detection of prostate cancer through medical imaging. The project is the first collaborative effort in the U.S. to explore pioneering artificial intelligence (AI) technologies for improving treatment of prostate cancer in veterans. "We are pleased to be collaborating with the VAGLAHS and Dr. Matthew Rettig, Chief of Hematology-Oncology, on the AI imaging platform, bringing together the largest integrated healthcare network in the U.S. with the leader in prostate cancer detection and monitoring,” Mark Baker, Progenics' CEO, said in a press release. “Progenics’ AI research program will provide the VAGLAHS, and in the future, the entire VA, with standardized, quantitative information to improve the quality of life, care and treatment of our Veterans with prostate cancer. We believe that artificial intelligence can be applied successfully to automate the segmentation, classification, and quantification of tumors, thereby enabling improved treatment decisions for men with prostate cancer,” he added.